Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting By Investing.com
Novel H2CasMab-2 Antigen Binding Area Proven to Preferentially Goal (NYSE:) HER2 Expressed on Tumor Cells in Preclinical Research Preliminary Low-Dose ...
